OTCMKTS:GTHP

Guided Therapeutics (GTHP) Stock Forecast, Price & News

$0.16

+0.06 (+57.25%)

(As of 06/9/2023 ET)

Compare

Today's Range: $0.09
▼
$0.16
50-Day Range: $0.11
▼
$0.28
52-Week Range: $0.06
▼
$0.60

Volume: 20,026 shs
Average Volume: 42,016 shs
Market Capitalization: $8.41 million

P/E Ratio: N/A
Dividend Yield: N/A
Price Target: N/A

Profile Chart Competitors Financials Headlines SEC Filings Short Interest

About Guided Therapeutics (OTCMKTS:GTHP) Stock

Guided Therapeutics, Inc. is a medical technology company, which engages in developing medical devices. It also focuses on the selling and marketing of its LuViva advanced cervical scan non-invasive cervical cancer detection device. The company was founded by Shabbir Bakir Bambot and Mark L. Faupel on October 27, 1992 and is headquartered in Norcross, GA.

Receive GTHP Stock News and Ratings via Email

Sign-up to receive the latest news and ratings for Guided Therapeutics and its competitors with MarketBeat's FREE daily newsletter.

GTHP Stock News Headlines

May 11, 2023 | americanbankingnews.com

Short Interest in Guided Therapeutics, Inc. (OTCMKTS:GTHP) Rises By 17,700.0%

April 20, 2023 | americanbankingnews.com

Contrasting AxoGen (NASDAQ:AXGN) and Guided Therapeutics (OTCMKTS:GTHP)

June 10, 2023 | Behind the Markets (Ad)

The single greatest medical breakthrough of all time?

We are on the cusp of a medical breakthrough. And soon, this single breakthrough could lead to the cure of over 6,000 genetic diseases, including Alzheimer's, heart disease, and even cancer! This reminds me of Amgen, where early investors made as much as 46,751% when they released their revolutionary drug to the market.

March 21, 2023 | americanbankingnews.com

Financial Contrast: Guided Therapeutics (OTCMKTS:GTHP) & Fc Global Realty (OTCMKTS:FCRE)

February 17, 2023 | abcnews.go.com

'It was a trap': Video shows American volunteer likely killed by guided missile in 'deliberate' Russian attack

November 9, 2022 | finance.yahoo.com

Guided Therapeutics Provides Update of Significant Progress in Chinese Clinical Study for Marketing Approval of the LuViva Advanced Cervical Scan

July 20, 2022 | finance.yahoo.com

Guided Therapeutics Receives Institutional Review Board Approval to Start Clinical Study for FDA Approval of the LuViva® Advanced Cervical Scan

June 9, 2022 | finance.yahoo.com

Impel Pharmaceuticals to Present Trudhesa® Data at the 64th Annual Meeting of the American Headache Society

June 10, 2023 | MarketBeat Internal (Ad)

Introducing MarketBeat All Access

Get real-time financial news and market data with MarketBeat All Access. Monitor your portfolio and the markets. Access our top stock picks, unbeatable research tools, best-in-class stock screeners, and proprietary research reports.

May 18, 2022 | stockhouse.com

Olive Resource Capital Announces Agreement to Acquire C$2.5M Portfolio of Assets

March 31, 2022 | finance.yahoo.com

Guided Therapeutics Announces Testing Completion of First 150 Patients in Chinese Clinical Study and Receives Milestone Payment of $177,740

November 17, 2021 | finance.yahoo.com

Guided Therapeutics Announces Start of Chinese Clinical Trial for Approval to Market and Sell LuViva in China

October 5, 2021 | finance.yahoo.com

Guided Therapeutics Ships LuViva Devices to China for Start of Clinical Trial; Receives Additional $100,000 Payment

October 26, 2020 | businesswire.com

Company Profile for Guided Therapeutics, Inc.

See More Headlines

GTHP Price History

30 days | 90 days | 365 days | Advanced Chart

GTHP Company Calendar

Today: 6/10/2023
Fiscal Year End: 12/31/2023

Get Stock Alerts

Industry, Sector and Symbol

Stock Exchange: OTCMKTS
Industry: Electromedical equipment
Sub-Industry: N/A
Sector: Medical
Current Symbol: OTCMKTS:GTHP
CUSIP: N/A
CIK: 924515
Web: www.guidedinc.com
Phone: (770) 242-8723
Fax: 770-242-8639
Employees: 6
Year Founded: N/A

Profitability

EPS (Most Recent Fiscal Year): N/A
Trailing P/E Ratio: N/A
Forward P/E Ratio: N/A
P/E Growth: N/A
Net Income: $-4,340,000.00
Net Margins: -4,276.71%
Pretax Margin: -15,676.67%
Return on Equity: N/A
Return on Assets: -161.73%

Debt

Debt-to-Equity Ratio: N/A
Current Ratio: 0.64
Quick Ratio: 0.49

Sales & Book Value

Annual Sales: $10,000.00
Price / Sales: 840.66
Cash Flow: N/A
Price / Cash Flow: N/A
Book Value: ($0.12) per share
Price / Book: -1.37

Miscellaneous

Outstanding Shares: 51,011,000
Free Float: 16,920,000
Market Cap: $8.41 million
Optionable: Not Optionable
Beta: 0.62

Key Executives

Mark L. Faupel
President, Chief Executive Officer & Director

Richard L. Fowler
Senior Vice President-Engineering

Key Competitors

View All Competitors

GTHP Stock - Frequently Asked Questions

How have GTHP shares performed in 2023?: Guided Therapeutics' stock was trading at $0.30 at the beginning of the year. Since then, GTHP shares have decreased by 45.1% and is now trading at $0.1648.
View the best growth stocks for 2023 here.
Are investors shorting Guided Therapeutics?: Guided Therapeutics saw a decrease in short interest during the month of May. As of May 15th, there was short interest totaling 7,700 shares, a decrease of 56.7% from the April 30th total of 17,800 shares. Based on an average trading volume of 118,100 shares, the days-to-cover ratio is presently 0.1 days.
View Guided Therapeutics' Short Interest.
What is Guided Therapeutics' stock symbol?: Guided Therapeutics trades on the OTCMKTS under the ticker symbol "GTHP."

How do I buy shares of Guided Therapeutics?: Shares of GTHP stock can be purchased through any online brokerage account. Popular online brokerages with access to the U.S. stock market include WeBull, Vanguard Brokerage Services, TD Ameritrade, E*TRADE, Robinhood, Fidelity, and Charles Schwab.
Compare Top Brokerages Here.
What is Guided Therapeutics' stock price today?: One share of GTHP stock can currently be purchased for approximately $0.16.
How much money does Guided Therapeutics make?: Guided Therapeutics (OTCMKTS:GTHP) has a market capitalization of $8.41 million and generates $10,000.00 in revenue each year.
How can I contact Guided Therapeutics?: Guided Therapeutics' mailing address is 5835 PEACHTREE CORNERS EAST SUITE D, PEACHTREE CORNERS GA, 30092. The official website for the company is www.guidedinc.com. The company can be reached via phone at (770) 242-8723, via email at bwells@guidedinc.com, or via fax at 770-242-8639.

This page (OTCMKTS:GTHP) was last updated on 6/10/2023 by MarketBeat.com Staff

Get 30 Days of MarketBeat All Access Free

Best-in-Class Portfolio Monitoring
View the latest news, buy/sell ratings, SEC filings and insider transactions for your stocks. Compare your portfolio performance to leading indices and get personalized stock ideas based on your portfolio.
Stock Ideas and Recommendations
Get daily stock ideas from top-performing Wall Street analysts. Get short term trading ideas from the MarketBeat Idea Engine. View which stocks are hot on social media with MarketBeat's trending stocks report.
Advanced Stock Screeners and Research Tools
Identify stocks that meet your criteria using seven unique stock screeners. See what's happening in the market right now with MarketBeat's real-time news feed. Export data to Excel for your own analysis.

Start Your 30-Day Free Trial